基于吉西他滨联合顺铂化疗方案分析参一胶囊对晚期非小细胞肺癌患者的疗效

Analysis of the effects of Shenyi Capsule on patients with advanced non-small cell lung cancer based on gemcitabine combined with cisplatin chemotherapy

目的:探究参一胶囊联合吉西他滨联合顺铂(gemcitabine plus cisplatin,GP)化疗方案对晚期非小细胞肺癌(non-small-cell lung carcinoma,NSCLC)患者免疫功能、炎症状态、外周血象的影响,以期为其临床应用提供研究依据。方法:选择2016年10月至2018年10月在我院就诊的80例晚期NSCLC患者为研究对象,采用随机数字表法将其分为观察组和对照组各40例,对照组采用吉西他滨联合顺铂(gemcitabine combined with cisplatin,GP方案)进行化疗,观察组在对照组基础上联合参一胶囊口服治疗,比较2组的临床疗效、免疫功能指标(T淋巴细胞亚群CD3^+、CD4^+、CD8^+及CD4^+/CD8^+值)、炎症因子[肿瘤坏死因子(tumor necrosis factor,TNF)-α、白细胞介素(interleukin,IL)-6及IL-10]水平及外周血象异常发生率。结果:观察组有效率、疾病控制率均明显高于对照组,治疗后2组患者CD3^+、CD4^+、CD8^+水平及CD4^+/CD8^+值均明显低于治疗前,但观察组CD3^+、CD4^+、CD8^+水平及CD4^+/CD8^+值明显高于对照组,治疗后对照组TNF-α、IL-6水平明显高于观察组,IL-10水平明显低于观察组,2组患者白细胞、血小板、血红蛋白下降发生率比较差异有统计学意义。结论:参一胶囊联合GP化疗对晚期NSCLC患者具有较好的疗效,该联合疗法不仅可以提高患者免疫功能,改善机体炎症状态,还可缓解外周血象异常,具有较好的安全性。

Objective:To explore the effects of Shenyi capsule combined with gemcitabine plus cisplatin(GP)chemotherapy on immune function,inflammatory status,toxic and peripheral hemogram in patients with advanced non-small-cell lung cancer(NSCLC),so as to provide research basis for its clinical application.Methods:A total of 80 patients with advanced NSCLC who were treated in our hospital from Oct.2016 to Oct.2018 were selected,and they were randomly divided into observation group(n=40)and control group(n=40)according to the random number table method.The control group received chemotherapy with gemcitabine combined with cisplatin,and the observation group received oral treatment with Shenyi capsule on the basis of control group.The clinical efficacy,immune function indexes(T lymphocyte subsets include CD3^+,CD4^+,CD8^+ and CD4^+/CD8^+values),inflammatory factors[tumor necrosis factor(TNF)-α,interleukin(IL)-6 and IL-10]and incidence of abnormal peripheral hemogram were compared between two groups.Results The effective rate and disease control rate in observation group were significantly higher than those in control group.After treatment,the levels of CD3^+,CD4^+,CD8^+ and CD4^+/CD8^+ values in the two groups were significantly lower than those before treatment,but the levels of these indicators in observation group were significantly higher than those in control group.After treatment,the levels of TNF-α,IL-6 in control group were significantly higher than those in observation group,while the level of IL-10 was significantly lower than observation group.There were statistically significant differences in the incidence of leukocyte,platelet and hemoglobin decline between the two groups.Conclusion:Shenyi capsule combined with GP chemotherapy had a good effect on patients with advanced NSCLC,which could not only improve the immune function and inflammatory status of patients,but also alleviate the toxic and peripheral abnormality and had a good safety.